This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nelson, R. A. Articles by Bernstein, L. Search for Related Content PubMed PubMed Citation Articles by Nelson, R. A. Articles by Bernstein, L.

Reproductive Factors and Risk of Intermediate- or High-Grade B-Cell Non-Hodgkin’s Lymphoma in Women

From the Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033.

Address reprint requests to Leslie Bernstein, PhD, University of Southern California/Norris Comprehensive Cancer Center, 1975 Zonal Avenue, KAM 506, Los Angeles, CA 90033; email: lbern{at}hsc.usc.edu

PURPOSE: The incidence rates of non-Hodgkin’s lymphoma (NHL) unrelated to human immunodeficiency virus infection are lower for women than for men; yet, few factors have been identified that may account for this difference in risk. NHL is difficult to study epidemiologically because this disorder represents a group of malignancies that differ in terms of morphologic presentation, immunologic features, genetic characteristics, prognosis, and etiology.

PATIENTS AND METHODS: We conducted a population-based case-control study in women to determine whether reproductive factors or hormonal exposures might be related to the risk of high- or intermediate-grade B-cell NHL. We interviewed 177 female residents of Los Angeles County who were diagnosed with high- or intermediate-grade B-cell NHL between 1989 and 1992; each case patient was individually matched on age and race to a control subject who lived in her neighborhood.

RESULTS: Women who had used oral contraceptives had significantly lower risk of intermediate- or high-grade NHL (multivariate odds ratio [OR] = 0.47; 95% confidence interval [CI], 0.26 to 0.86) than women who had never used these compounds. Among parous women, those who had used lactation suppressants (which contain high levels of estrogen) had significantly lower risk of NHL (multivariate OR = 0.50; 95% CI, 0.29 to 0.85) than unexposed women. Postmenopausal women had a somewhat greater risk of NHL than premenopausal women, whereas those postmenopausal women who had used hormone replacement therapy (HRT) (primarily estrogen) had somewhat lower risk than those who had not used HRT.

CONCLUSION: Exogenous estrogens seem to have a protective effect on the risk of high- and intermediate-grade B-cell NHL. Although the mechanisms for such protection are not known, alterations in immune reactivity, cytokine expression, or B-cell modulation may play a role.

The ideas and opinions expressed herein are those of the authors, and no endorsement by the State of California, or the California Public Health Foundation is intended or should be inferred.

This article has been cited by other articles:

				R. Calderon-Margalit, Y. Friedlander, R. Yanetz, K. Kleinhaus, M. C. Perrin, O. Manor, S. Harlap, and O. Paltiel Cancer Risk After Exposure to Treatments for Ovulation Induction Am. J. Epidemiol., November 26, 2008; (2008) kwn318v1. [Abstract] [Full Text] [PDF]

				J. S. Lee, P. M. Bracci, and E. A. Holly Non-Hodgkin Lymphoma in Women: Reproductive Factors and Exogenous Hormone Use Am. J. Epidemiol., August 1, 2008; 168(3): 278 - 288. [Abstract] [Full Text] [PDF]

				G. Corrao, A. Zambon, V. Conti, F. Nicotra, C. La Vecchia, C. Fornari, G. Cesana, P. Contiero, G. Tagliabue, R. E. Nappi, et al. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation Ann. Onc., January 1, 2008; 19(1): 150 - 155. [Abstract] [Full Text] [PDF]

				G. L. Bond, K. M. Hirshfield, T. Kirchhoff, G. Alexe, E. E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, W. Hait, et al. MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res., May 15, 2006; 66(10): 5104 - 5110. [Abstract] [Full Text] [PDF]

				C. F. Skibola, P. M. Bracci, R. A. Paynter, M. S. Forrest, L. Agana, T. Woodage, K. Guegler, M. T. Smith, and E. A. Holly Polymorphisms and Haplotypes in the Cytochrome P450 17A1, Prolactin, and Catechol-O-Methyltransferase Genes and Non-Hodgkin Lymphoma Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2391 - 2401. [Abstract] [Full Text] [PDF]

				E. T. Chang, H. Hjalgrim, K. E. Smedby, M. Akerman, E. Tani, H. E. Johnsen, B. Glimelius, H.-O. Adami, and M. Melbye Body Mass Index and Risk of Malignant Lymphoma in Scandinavian Men and Women J Natl Cancer Inst, February 2, 2005; 97(3): 210 - 218. [Abstract] [Full Text] [PDF]

				Y. Zhang, T. R. Holford, B. Leaderer, P. Boyle, S. H. Zahm, B. Zhang, K. Zou, L. M. Morton, P. H. Owens, S. Flynn, et al. Menstrual and Reproductive Factors and Risk of Non-Hodgkin's Lymphoma among Connecticut Women Am. J. Epidemiol., October 15, 2004; 160(8): 766 - 773. [Abstract] [Full Text] [PDF]

				S. L. Glaser, C. A. Clarke, R. A. Nugent, C. B. Stearns, and R. F. Dorfman Reproductive Factors in Hodgkin's Disease in Women Am. J. Epidemiol., September 15, 2003; 158(6): 553 - 563. [Abstract] [Full Text] [PDF]

				P. A. Volberding, K. R. Baker, and A. M. Levine Human Immunodeficiency Virus Hematology Hematology, January 1, 2003; 2003(1): 294 - 313. [Abstract] [Full Text] [PDF]

				J. R. Cerhan, C. M. Vachon, T. M. Habermann, S. M. Ansell, T. E. Witzig, P. J. Kurtin, C. A. Janney, W. Zheng, J. D. Potter, T. A. Sellers, et al. Hormone Replacement Therapy and Risk of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1466 - 1471. [Abstract] [Full Text] [PDF]

				A. M. Levine, D. T. Scadden, J. A. Zaia, and A. Krishnan Hematologic Aspects of HIV/AIDS Hematology, January 1, 2001; 2001(1): 463 - 478. [Abstract] [Full Text] [PDF]